Literature DB >> 22535654

The choice of vascular access for therapeutic apheresis.

Kambiz Kalantari1.   

Abstract

Therapeutic apheresis (TA) is performed using either centrifugation-based or filter-based systems. The blood flow rate (BFR) used for TA using centrifugation-based systems is less than 100 mL/min. Because of this low BFR requirement, even peripheral veins can be considered as an option for TA, especially for less-frequent treatments and those performed for short periods. Other options for vascular access (VA) include central venous catheters (temporary or tunneled), totally implantable ports, and arteriovenous fistulae (AVF) or grafts (AVG). Nontunneled catheters should be considered as the choice of VA for relatively short-term treatments mainly in the inpatient settings. For long-term treatments, ports and tunneled catheters should be considered because of lower rates of infections compared to nontunneled catheters. However, studies in hemodialysis (HD) patients have demonstrated significantly higher morbidity and mortality rates associated with the use of tunneled catheters as compared to AVF. Therefore, if TA is being considered for several years, AVG and AVF would be the preferred options of VA. Studies in HD population indicate far better outcomes with the use of AVF as compared to AVG. This article, as presented at the Therapeutic Apheresis Academy in September 2011, is an overview of the available VA options for TA based on indication and duration of treatment. Pros and cons of each option are mentioned briefly. Finally, for those considered for AVF placement for chronic TA, specific recommendations are made for the care of AVF based on our own experience at University of Virginia.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22535654     DOI: 10.1002/jca.21225

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  5 in total

1.  Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre.

Authors:  Agnieszka Mickiewicz; Justyna Borowiec-Wolna; Witold Bachorski; Natasza Gilis-Malinowska; Rafał Gałąska; Grzegorz Raczak; Magdalena Chmara; Bartosz Wasąg; Miłosz J Jaguszewski; Marcin Fijałkowski; Marcin Gruchała
Journal:  Cardiol J       Date:  2018-09-20       Impact factor: 2.737

2.  Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Sara K Vesely; Spero R Cataland; Paul Coppo; Brian Geldziler; Alfonso Iorio; Masanori Matsumoto; Reem A Mustafa; Menaka Pai; Gail Rock; Lene Russell; Rawan Tarawneh; Julie Valdes; Flora Peyvandi
Journal:  J Thromb Haemost       Date:  2020-09-11       Impact factor: 5.824

3.  Short-term central venous catheter complications in patients with sickle cell disease who undergo apheresis.

Authors:  Mahmut Yeral; Can Boga; Levent Oguzkurt; Suheyl Asma; Mutlu Kasar; Ilknur Kozanoglu
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

4.  Treatment of MuSK-Associated Myasthenia Gravis.

Authors:  Khalid El-Salem; Ahmed Yassin; Kefah Al-Hayk; Salma Yahya; Duha Al-Shorafat; Said S Dahbour
Journal:  Curr Treat Options Neurol       Date:  2014-04       Impact factor: 3.972

Review 5.  Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective.

Authors:  Eugeni Domènech; Joan-Ramon Grífols; Ayesha Akbar; Axel U Dignass
Journal:  World J Gastroenterol       Date:  2021-03-14       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.